NASDAQ:MRTX Mirati Therapeutics (MRTX) Stock Forecast, Price & News $38.26 +1.25 (+3.38%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$36.85▼$38.4050-Day Range$36.54▼$49.4952-Week Range$35.70▼$101.30Volume1.13 million shsAverage Volume1.02 million shsMarket Capitalization$2.23 billionP/E RatioN/ADividend YieldN/APrice Target$76.93 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Mirati Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside101.1% Upside$76.93 Price TargetShort InterestHealthy11.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.68Upright™ Environmental ScoreNews Sentiment0.06Based on 13 Articles This WeekInsider TradingSelling Shares$200,252 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($12.55) to ($10.96) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.18 out of 5 starsMedical Sector355th out of 983 stocksPharmaceutical Preparations Industry165th out of 486 stocks 3.3 Analyst's Opinion Consensus RatingMirati Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $76.93, Mirati Therapeutics has a forecasted upside of 101.1% from its current price of $38.26.Amount of Analyst CoverageMirati Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted11.62% of the outstanding shares of Mirati Therapeutics have been sold short.Short Interest Ratio / Days to CoverMirati Therapeutics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Mirati Therapeutics has recently decreased by 14.75%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMirati Therapeutics does not currently pay a dividend.Dividend GrowthMirati Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirati Therapeutics is -0.68. Previous Next 2.3 News and Social Media Coverage News SentimentMirati Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Mirati Therapeutics this week, compared to 3 articles on an average week.Search Interest20 people have searched for MRTX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirati Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,252.00 in company stock.Percentage Held by InsidersOnly 3.47% of the stock of Mirati Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirati Therapeutics are expected to grow in the coming year, from ($12.55) to ($10.96) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirati Therapeutics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirati Therapeutics is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirati Therapeutics has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Mirati Therapeutics (NASDAQ:MRTX) StockMirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.Read More Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MRTX Stock News HeadlinesJune 2, 2023 | americanbankingnews.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Receives $78.23 Consensus Target Price from AnalystsJune 1, 2023 | finance.yahoo.comMirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023June 4, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 30, 2023 | americanbankingnews.comMirati Therapeutics, Inc. (NASDAQ:MRTX) Short Interest UpdateMay 30, 2023 | americanbankingnews.comShort Interest in Mirati Therapeutics, Inc. (NASDAQ:MRTX) Declines By 14.8%May 30, 2023 | americanbankingnews.comMirati Therapeutics, Inc. Forecasted to Post FY2024 Earnings of ($10.01) Per Share (NASDAQ:MRTX)May 27, 2023 | americanbankingnews.comInvestors Buy Large Volume of Call Options on Mirati Therapeutics (NASDAQ:MRTX)May 26, 2023 | americanbankingnews.comJamie Christensen Sells 619 Shares of Mirati Therapeutics, Inc. (NASDAQ:MRTX) StockJune 4, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 26, 2023 | americanbankingnews.comMirati Therapeutics (NASDAQ:MRTX) Upgraded to "Outperform" by OppenheimerMay 25, 2023 | msn.comMirati tumbles after study failure for cancer drug; Oppenheimer upgradesMay 25, 2023 | markets.businessinsider.comJonesTrading Sticks to Their Buy Rating for Mirati Therapeutics (MRTX)May 25, 2023 | msn.comBMO Capital Maintains Mirati Therapeutics (MRTX) Market Perform RecommendationMay 25, 2023 | msn.comBarclays Maintains Mirati Therapeutics (MRTX) Overweight RecommendationMay 25, 2023 | americanbankingnews.comMirati Therapeutics (NASDAQ:MRTX) Price Target Cut to $40.00 by Analysts at BMO Capital MarketsMay 25, 2023 | markets.businessinsider.comBarclays Remains a Buy on Mirati Therapeutics (MRTX)May 25, 2023 | americanbankingnews.comMirati Therapeutics (NASDAQ:MRTX) PT Lowered to $75.00 at BarclaysMay 20, 2023 | seekingalpha.comMirati: The High Stakes Of Krazati's Market Performance Amidst Dwindling Cash (Rating Downgrade)May 17, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Mirati Therapeutics (MRTX)May 14, 2023 | finance.yahoo.comGrowth Investors: Industry Analysts Just Upgraded Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Forecasts By 23%May 14, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for Mirati Therapeutics, Inc. (NASDAQ:MRTX) Raised by AnalystMay 12, 2023 | msn.comOppenheimer Reiterates Mirati Therapeutics (MRTX) Perform RecommendationMay 11, 2023 | msn.comCitigroup Maintains Mirati Therapeutics (MRTX) Neutral RecommendationMay 11, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Mirati Therapeutics (MRTX), NuVasive (NUVA) and Zentalis Pharmaceuticals (ZNTL)May 11, 2023 | markets.businessinsider.comAnalyst Expectations for Mirati Therapeutics's FutureMay 11, 2023 | americanbankingnews.comMirati Therapeutics (NASDAQ:MRTX) Price Target Lowered to $77.00 at Stifel NicolausMay 11, 2023 | markets.businessinsider.comMirati Therapeutics (MRTX) Receives a Buy from JMP SecuritiesSee More Headlines MRTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRTX Company Calendar Last Earnings5/09/2023Today6/04/2023Next Earnings (Estimated)8/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRTX CUSIPN/A CIK1576263 Webwww.mirati.com Phone(858) 332-3410FaxN/AEmployees413Year Founded2013Price Target and Rating Average Stock Price Forecast$76.93 High Stock Price Forecast$188.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+101.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($12.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-740,870,000.00 Net Margins-3,901.06% Pretax Margin-3,898.38% Return on Equity-71.90% Return on Assets-61.18% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.51 Sales & Book Value Annual Sales$18.89 million Price / Sales117.83 Cash FlowN/A Price / Cash FlowN/A Book Value$14.82 per share Price / Book2.58Miscellaneous Outstanding Shares58,187,000Free Float56,168,000Market Cap$2.23 billion OptionableOptionable Beta1.02 Social Links Key ExecutivesDavid D. MeekChief Executive Officer & DirectorCharles M. BaumPresident, Director & Head-Research & DevelopmentLaurie D. StelzerChief Financial OfficerJames G. ChristensenChief Scientific OfficerAlan Bart SandlerChief Medical Officer & Executive Vice PresidentKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHAkero TherapeuticsNASDAQ:AKROBridgeBio PharmaNASDAQ:BBIOHarmony BiosciencesNASDAQ:HRMYHUTCHMEDNASDAQ:HCMView All CompetitorsInsiders & InstitutionsLaurie StelzerSold 4,647 sharesTotal: $172,217.82 ($37.06/share)Jamie ChristensenSold 619 sharesTotal: $28,034.51 ($45.29/share)New York State Common Retirement FundBought 835 shares on 5/18/2023Ownership: 0.399%Thrivent Financial for LutheransSold 61,734 shares on 5/17/2023Ownership: 0.123%Balyasny Asset Management L.P.Bought 15,183 shares on 5/16/2023Ownership: 0.104%View All Insider TransactionsView All Institutional Transactions MRTX Stock - Frequently Asked Questions Should I buy or sell Mirati Therapeutics stock right now? 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRTX shares. View MRTX analyst ratings or view top-rated stocks. What is Mirati Therapeutics' stock price forecast for 2023? 12 Wall Street research analysts have issued 12-month price targets for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $40.00 to $188.00. On average, they predict the company's share price to reach $76.93 in the next year. This suggests a possible upside of 101.1% from the stock's current price. View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts. How have MRTX shares performed in 2023? Mirati Therapeutics' stock was trading at $45.31 at the start of the year. Since then, MRTX shares have decreased by 15.6% and is now trading at $38.26. View the best growth stocks for 2023 here. Are investors shorting Mirati Therapeutics? Mirati Therapeutics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 6,760,000 shares, a decrease of 14.8% from the April 30th total of 7,930,000 shares. Based on an average daily trading volume, of 981,200 shares, the short-interest ratio is presently 6.9 days. View Mirati Therapeutics' Short Interest. When is Mirati Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023. View our MRTX earnings forecast. How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings results on Tuesday, May, 9th. The biotechnology company reported ($3.18) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.29. The biotechnology company earned $7.17 million during the quarter, compared to the consensus estimate of $4.80 million. Mirati Therapeutics had a negative net margin of 3,901.06% and a negative trailing twelve-month return on equity of 71.90%. Mirati Therapeutics's revenue was up 910.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($3.40) EPS. What ETFs hold Mirati Therapeutics' stock? ETFs with the largest weight of Mirati Therapeutics (NASDAQ:MRTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU). What is Mirati Therapeutics' stock symbol? Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX." Who are Mirati Therapeutics' major shareholders? Mirati Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (6.35%), BlackRock Inc. (5.57%), Wellington Management Group LLP (4.64%), State Street Corp (3.97%), Price T Rowe Associates Inc. MD (3.04%) and Perceptive Advisors LLC (2.71%). Insiders that own company stock include Benjamin Hickey, Boxer Capital, Llc, Bruce L A Carter, Charles M Baum, Craig A Johnson, Daniel Faga, David D Meek, Henry J Fuchs, Jamie Christensen, Julie M Cherrington, Julie M Cherrington, Laurie Stelzer, Ltd Braslyn, Maria E Martinez and Vickie S Reed. View institutional ownership trends. How do I buy shares of Mirati Therapeutics? Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Mirati Therapeutics' stock price today? One share of MRTX stock can currently be purchased for approximately $38.26. How much money does Mirati Therapeutics make? Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.23 billion and generates $18.89 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($12.96) on an earnings per share basis. How many employees does Mirati Therapeutics have? The company employs 413 workers across the globe. Does Mirati Therapeutics have any subsidiaries? The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..Read More How can I contact Mirati Therapeutics? Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com. This page (NASDAQ:MRTX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.